A leading Chinese company on Wednesday announced it has sought formal approval from authorities to bring its COVID-19 vaccine to the market, state-run media said
Sinopharm's vice-general manager Shi Shengyi said the company has collected data from major countries carrying out its vaccine's clinical trials and the results are expected to be favorable, Global Times reported.
#PakEconomyOnTrack— Ifrah Shareef (@SindhiiChokri) November 23, 2020
Sinopharm’s chairman told state media last month that a potential vaccine could be ready by the end of this year, with Phase 3 testing expected to be completed in about three months.@ItxOmerOfficial@AHMADRAZA9000@Jaaamaall2
Earlier, the company said that it had submitted the vaccine's Phase-3 clinical data to China's State Food and Drug Administration and was in the process of giving more detailed data.
The company said it is in the final stage before marketization and is now making approval of the vaccine its top priority.
The company is expected to release its vaccine's Phase-3 data after the government approval.
"Our data is evaluated by relevant departments following protocols even stricter than in some Western countries, and we are in close communication with the WHO," the company representative further said.
Last month, China claimed that its experimental vaccines for protection against COVID-19 have shown "no adverse reaction".
According to Chinese officials, the country has 13 vaccine candidates entering clinical trials, including four in Phase-3 trials.
Over 100 vaccines to prevent coronavirus are at different stages of development. The US drug maker Pfizer and German biotech company BioNTech last week said that their coronavirus vaccine is 95% effective, upgrading an earlier estimate of 90%.
Their announcement came days after US drug company Moderna said its own shot was 94.5% effective.
This article has been adapted from its original source.
© Copyright Andolu Ajansi